Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

Company to Hold Conference Call at 10:30 A.M. Eastern Time Today

NEW HAVEN, Conn., Jan. 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on the Phase III trial (Vion Study CLI-037) of its lead anti-cancer agent, Cloretazine(R) (VNP40101M), in combination with cytarabine in relapsed acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer, said, "We are pleased with the FDA's decision to lift the clinical hold on Cloretazine(R) (VNP40101M) in combination with cytarabine in relapsed AML, and are now poised to move forward with the clinical development of Cloretazine(R) (VNP40101M) in the relapsed setting."

While this trial remains blinded overall, a portion of data on 210 patients was unblinded for review at interim analysis. The Company's medical consultants and external independent reviewers performed a comprehensive safety analysis of Vion Study CLI-037. This analysis concluded that the combined myelosuppressive effects of Cloretazine(R) (VNP40101M) and cytarabine given at the dose and schedule at which they were combined in the trial, in conjunction with the poor hematologic reserve of patients with relapsed AML, were major factors in the difference in mortality seen between the two arms of the study. A review of records from patients who died did not suggest any previously unreported toxicity for Cloretazine(R) or cytarabine.

There was an increase in the response rate observed on the Cloretazine(R) (VNP40101M) and cytarabine arm of the trial relative to the cytarabine and placebo arm, despite the difference in deaths between the two arms. Given this observed increase in response
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, August 6, 2015 to discuss ... Interested parties may access the live conference ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... a leading designer of integrated medical imaging display systems, ... Medical achieved significant growth in sales, an expansion of ... Carrot Medical, recognized as a market leader, is the ... medical images and other visual data onto a single, ...
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... ("Valeant"), its wholly owned indirect subsidiary, launched its offer ... unsecured notes (the "Notes"). The Notes will ... as amended (the "Securities Act"), or any state securities ...
Cached Medicine Technology:Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011 2Valeant Launches Senior Notes Offering 2Valeant Launches Senior Notes Offering 3
(Date:8/1/2015)... ... August 01, 2015 , ... ... are in “a trending profession” that comprises a growing percentage of U.S. physicians, ... most. , That was one part of the message delivered by John W. ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of ... the HOPE Movement of EvolvHealth. In what has been a long-term relationship between the ... their missions of purpose together to change the course of the network marketing industry. ...
(Date:8/1/2015)... ... , ... “ reTXT ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... and delete any message including ones already sent. , While text messaging has more ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... Alexandria, VA (PRWEB) , ... July 31, 2015 ... ... Foundation) introduced its new store run by GoodThreads. The store can be accessed ... products and designs, many of which are customizable. The best part: whenever a ...
Breaking Medicine News(10 mins):Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... Foundation Applauds Patient Education In New National Guidelines, ... children and adults with asthma are getting a back-to-school ... U.S. health,officials, which affirm the primary importance of patient ... live without limits and,to improve their quality of life., ...
... report that exercise and yoga can help maintain ... in women with early-stage breast cancer. The first ... physical fitness, self-esteem and body composition, and that ... study demonstrated that yoga was particularly beneficial for ...
... Healthcare Technology Executive Brings Over 20 Years Of Experience ... in Sales, Marketing And Operational Excellence, ... (Nasdaq: MEDW ) announced the appointment of Thomas ... joins Mediware,following more than 20 years with 3M,s healthcare ...
... The results of a clinical trial, published in ... when used as part of routine therapy, high-dose ibuprofen ... in children with cystic fibrosis (CF). , Headed by ... Montreal Childrens Hospital of the McGill University Health Centre, ...
... Inc. (Nasdaq and SWX: BMRN) announced today that Emil,Kakkis, ... a,company update at the Bear Stearns 20th Annual Healthcare ... at 3:00 p.m. ET. Interested parties may access ... section of the BioMarin website, http://www.BMRN.com . A,replay ...
... a new study indicate a strong link between the ... cognitive impairment (MCI), often a harbinger of Alzheimer,s disease. ... binds specific substances. Researchers found reduced levels of LR11, ... tissue of people diagnosed with MCI. In addition, the ...
Cached Medicine News:Health News:School is Cool for Asthma Patients of All Ages 2Health News:Exercise and yoga improves quality of life in women with early-stage breast cancer 2Health News:Exercise and yoga improves quality of life in women with early-stage breast cancer 3Health News:Mediware Names Thomas K. Mann Chief Executive Officer 2Health News:Low level of neuronal receptor linked to mild cognitive impairment and Alzheimer's disease 2
For vacuum-driven processing of spin columns; Reduced sample handling and accelerated processing; Parallel sample processing using QIAGEN spin columns; Easy cleaning of internal components by simpl...
Inquire...
... allows processing of up to 24 spin columns in ... columns into and out of a centrifuge. The ... savings rapid vacuum-driven purification and cleanup of ... Convenience minimal hands-on-time ...
... Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years ... ... ... ...
Medicine Products: